![]() Miller serves on the editorial board for Blood and is a reviewer for a number of journals and NIH grants. He is a member of numerous societies such as the American Society of Hematology, the American Association of Immunologists, and a member of the American Society of Clinical Investigation since 1999. He has more than 25 years of experience studying the biology of NK cells and other immune effector cells and their use in clinical immunotherapy with over 275 peer-reviewed publications. He is the Deputy Director of the University of Minnesota Masonic Comprehensive Cancer Center. Miller is currently a Professor of Medicine at the University of Minnesota, Division of Hematology, Oncology and Transplantation. He has led an independent basic, translational, and early phase clinical research program since joining the faculty of Washington University School of Medicine in 2008.ĭr. ![]() Timothy Ley at Washington University School of Medicine. He conducted post-doctoral research studying the mechanisms of lymphocyte cytotoxicity with Dr. in Immunology from Ohio State University, performing graduate training in the laboratory of Michael Caligiuri studying human NK cells. His clinical interests are hematologic malignancies, hematopoietic cell transplantation, and cellular immunotherapy.ĭr. His laboratory identified human memory NK cells differentiating after stimulation through combined cytokine receptors and pioneered translating NK cell memory as a cellular immunotherapy for leukemia. Fehniger leads a research team focused on mechanisms of NK cell development and function, strategies to enhance immune responses to cancer, and lymphoma immunogenomics. ![]() Fehniger is a Professor of Medicine at Washington University School of Medicine, Scientific Co-Director of the Center for Gene and Cellular Immunotherapy, and Co-Leader of the lymphoma program at the Siteman Cancer Center. Fehniger is a physician-scientist with over 25 years of experience in Immunology and Oncology. He spent four years at the University of Rochester School of Medicine before moving to Washington University where he now leads the Division of Oncology.ĭr. He completed his fellowship in Division of Hematology-Oncology, UCLA School of Medicine, where he became Assistant professor. He conducted his internship and residency at Parkland Memorial Hospital, where he became chief resident. and Ph.D from the University of Rochester. These studies include identification of genetic abnormalities in human leukemias, understanding processes involving stem cell and leukemia cell trafficking, adoptive cellular therapy and clinical and translational programs in both leukemia/MDS and stem cell transplantation.ĭr. His research focuses on fundamental and translational aspects of leukemia and stem cell biology. He is the Deputy Director of Siteman Cancer Center and Director of the Washington University Center for Gene and Cellular Immunotherapy. DiPersio is the Chief of Oncology at Washington University School of Medicine, where he is the Virginia E.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |